HELPCybin D/B/A Helus Pharma
$6.24-31% 1Y
$6.24
$3.8752 weeks$14.03
Is it safe?
Watch
2 to watch, 4 without dataCaution warranted: heavy debt (CCC) and big price swings.
Credit gradeCCCderived · Mar 31, 2025
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Drawdown risk80% volderived · Oct 8, 2026
Large price swings, high volatility. Worst drawdown -97% · now 23% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can HELP take a bad year?
The deepest fall in HELP's price history on file is −97%; it is 23% below its high today.
−97%
Worst drawdown on file · −23% today
- Annualised volatility
- 80%
Annualised volatility · three times the market's own swing
Details›
- Cash and short-term investments
- $135M
- EBITDA, trailing twelve months
- −$134M
- Operating profit, trailing twelve months
- −$135M
- Annualised volatilitytwo years of daily moves
- 80%
- Worst drawdown on file
- −97%
- Below its 52-week high
- 23%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.